Real-World study checks safety of apixaban in the very elderly
NCT ID NCT04586972
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at nearly 1,000 people aged 80 and older with atrial fibrillation (an irregular heartbeat) who were newly prescribed the blood thinner apixaban. Researchers tracked bleeding events and how well the dose matched each patient's needs. The goal was to gather real-world safety data in this older group, who are often left out of drug trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- apixaban (a blood thinner)
- What this could lead to
- If successful, this study could help doctors better understand how to safely use apixaban in very elderly patients with atrial fibrillation.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONVALVULAR ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Geriatric Department, Broca Hospital
Paris, IIe-de-France, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.